Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
1.580
+0.010 (0.64%)
Aug 8, 2025, 10:51 AM - Market open
New Relic Employees
As of December 31, 2024, Aclaris Therapeutics had 64 total employees, including 61 full-time and 3 part-time employees. The number of employees decreased by 27 or -29.67% compared to the previous year.
Employees
64
Change (1Y)
-27
Growth (1Y)
-29.67%
Revenue / Employee
$262,328
Profits / Employee
-$2,103,938
Market Cap
171.08M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 64 | -27 | -29.67% |
Dec 31, 2023 | 91 | -14 | -13.33% |
Dec 31, 2022 | 105 | 28 | 36.36% |
Dec 31, 2021 | 77 | 17 | 28.33% |
Dec 31, 2020 | 60 | -17 | -22.08% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ACRS News
- 1 day ago - Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 days ago - Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints - GlobeNewsWire
- 11 days ago - Aclaris Therapeutics Announces Leadership Transition - GlobeNewsWire
- 5 weeks ago - Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes - GlobeNewsWire
- 6 weeks ago - Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference - GlobeNewsWire
- 6 weeks ago - Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052 - GlobeNewsWire
- 2 months ago - Aclaris Therapeutics to Participate in Two June Healthcare Conferences - GlobeNewsWire
- 3 months ago - Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series - GlobeNewsWire